Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome

European Journal of Clinical Investigation

Volumn 38, Issue 10, 2008, Pages 743-751

  Chan, D C ^a   Watts, G F ^a   Ng, T W K ^a   Yamashita, S ^b   Barrett, P H R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adipocytokines; Cardiovascular disease; Lifestyle intervention; Obesity; Triglyceride rich lipoproteins

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; APOLIPOPROTEIN B48; APOLIPOPROTEIN C3; CHOLESTEROL; INSULIN; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RETINOL BINDING PROTEIN 4; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; HUMAN; IMMUNOASSAY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CONTROL; WEIGHT REDUCTION;

ADULT; APOLIPOPROTEIN B-48; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CHOLESTEROL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LINEAR MODELS; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; TRIGLYCERIDES; WEIGHT LOSS;

EID: 52149092766     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.02019.x     Document Type: Article

References (47)

1. Despres JP. Dyslipidaemia and obesity. Baillieres Clin Endocrinol Metab 1994 8 : 629 60.
2. Chan DC, Watts GF, Barrett PHR, Mamo JCL, Redgrave TG. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem 2002 48 : 278 83.
3. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004 89 : 2595 600.
4. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol 1995 6 : 209 14.
5. Riches FM, Watts GF, Naoumova RP, Kelly JM, Croft KD, Thompson GR. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes Relat Metab Disord 1998 22 : 414 23.
6. Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PHR. Apolipoprotein B100 kinetics in visceral obesity: associations with plasma apolipoprotein CIII concentrations. Metabolism 2002 51 : 1041 6.
7. Smith D, Watts GF, Dane-Stewart CA, Mamo JCL. Postprandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B-48 in the fasting state. Eur J Clin Invest 1999 29 : 204 9.
8. Mero N, Malmstrom R, Steiner G, Taskinen MR, Syvanne M. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis 2000 150 : 167 77.
9. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PW, Ordovas JM et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001 154 : 229 36.
10. Twickler TB, Dallinga-Thie GM, Cohn JS, Chapman MJ. Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype. Circulation 2004 109 : 1918 25.
11. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001 12 : 297 304.
12. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation 2000 102 : 1886 92.
13. Havel PJ. Update on Adipocyte Hormones: regulation of energy balance and carbohydrate/lipid Metabolism. Diabetes 2004 53 : 143 51.
14. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Comm 1999 257 : 79 83.
15. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000 20 : 1595 9.
16. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002 8 : 1288 95.
17. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM et al. Serum retinol binding protein-4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005 436 : 356 62.
18. Janke J, Engeli S, Boschmann M, Adams F, Böhnke J, Luft FC et al. Retinol-binding protein 4 in human obesity. Diabetes 2006 55 : 2805 10.
19. Chan DC, Watts GF, Ng TWK, Uchida Y, Sakai N, Yamashita S et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem 2005 51 : 578 85.
20. Ng TWK, Watts GF, Farvid MS, Chan DC, Barrett PHR. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005 54 : 795 802.
21. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004 279 : 12152 62.
22. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 112 : 2735 52.
23. Riches FM, Watts GF, Hua J, Stewart GR, Naoumova RP, Barrett PHR. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab 1999 84 : 2854 61.
24. Wai TWK, Watts GF, Barrett PHR, Rye KA, Chan DC. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care 2007 30 : 2945 50.
25. Alberti KGMM, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005 366 : 1059 62.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 : 412 9.
27. Sakai N, Uchida Y, Ohashi K, Hibuse T, Saika Y, Tomari Y et al. Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res 2003 44 : 1256 62.
28. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 1993 223 : 53 71.
29. Fernandez M, Metghalchi S, Vega-López S, Conde-Knape K, Lohman T, Cordero-MacIntyre Z. Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women. J Nutr Biochem 2004 15 : 717 21.
30. James AP, Watts GF, Barrett PHR, Smith D, Pal S, Chan DC et al. Effect of weight loss on postprandial lipemia and low-density lipoprotein receptor binding in overweight men. Metabolism 2003 52 : 136 41.
31. Polak J, Kovacova Z, Jacek M, Klimcakova E, Kovacikova M, Vitkova M et al. An increase in plasma adiponectin multimeric complexes follows hypocaloric diet-induced weight loss in obese and overweight pre-menopausal women. Clin Sci 2007 112 : 557 65.
32. Bobbert T, Rochlitz H, Wegewitz U, Akpulat S, Mai K, Weickert MO et al. Changes of adiponectin oligomer composition by moderate weight loss. Diabetes 2005 54 : 2712 9.
33. Reaven GM, Chen YD. Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Rev 1988 4 : 639 52.
34. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000 21 : 697 738.
35. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 2000 7 : 325 31.
36. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bendadoun A et al. Effects of the PPARy aginist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2006 115 : 1323 32.
37. Chen M, Breslow JL, Li W, Leff T. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res 1994 35 : 1918 24.
38. Dallongeville J, Bauge E, Lebel P, Fruchart JC. Fat ingestion is associated with increased levels of apoC-III- and apoE-B-containing lipoprotein particles in humans. Eur J Clin Invest 1997 27 : 1055 60.
39. Duez H, Lamarche B, Valero R, Pavlic M, Proctor S, Xiao CT et al. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 2008 117 : 2369 76.
40. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003 46 : 459 69.
41. Jia W, Wu H, Bao Y, Wang C, Lu J, Zhu J et al. Association of serum retinol binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin Endocrinol Metab 2007 92 : 3224 9.
42. Vitkova M, Klimcakova E, Kovacikova M, Valle C, Moro C, Polak J et al. Plasma levels and adipose tissue messenger ribonucleic acid expression of retinol-binding protein 4 are reduced during calorie restriction in obese subjects but are not related to diet-induced changes in insulin sensitivity. J Clin Endocrinol Metab 2007 92 : 2330 5.
43. Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK et al. Weight loss-associated induction of peroxisome proliferator-activated receptor- and peroxisome proliferator-activated receptor-correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 2004 110 : 3259 69.
44. Blüher M, Brennan AM, Kelesidis T, Kratzsch J, Fasshauer M, Kralisch S et al. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care 2007 30 : 280 5.
45. Haider DG, Schindler K, Prager G, Bohdjalian A, Luger A, Wolzt M et al. Serum retinol-binding protein 4 Is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 2007 92 : 1168 71.
46. Ooi TC, Cousins M, Ooi DS, Steiner G, Uffelman KD, Nakajima K et al. Postprandial remnant-like lipoproteins in hypertriglyceridemia. J Clin Endocrinol Metab 2001 86 : 3134 42.
47. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006 114 : 681 7.